SAN DIEGO, July 26, 2017 /PRNewswire/ --
Zander Therapeutics, Inc., a subsidiary of Entest BioMedical Inc. (ENTB) reported that researchers for Regen BioPharma Inc. have identified what the company believes to be a strong activator for modulating checkpoint NR2F6. This is significant to Zander Therapeutics for two reasons; Zander is the exclusive licensee of Regen BioPharma's technology for veterinary applications and the study involved small samples of dog blood used in ex vivo studies.
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as inflammation and lupus.
"We tested three recently identified agonists which share a privileged structure for their ability to inhibit cytokine production in stimulated canine immune cells," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. "After stimulating the immune cells in the presence or absence of our compounds, we measured the cytokines IL-2, IL-1β, TNFα, IFN-ɣ, and IL-17a which are well-known to mediate many inflammatory and autoimmune-related diseases. Remarkably, our compounds inhibited IL-17a and IL-2, had a modest effect on TNFα and had no effect on IL-1β and IFN-ɣ secretion. This discovery gives us insight into the mechanism of action of these drugs and paves the way forward for optimizing these compounds."
"Zander believes the Regen BioPharma studies not only create a viable compound for treating autoimmunity and inflammation in dogs (and potentially other animals) but lay a solid foundation for refining inhibitors of checkpoint NR2F6 which potentially will lead to a small molecule therapy for treating dogs with cancer. With this important series of experiments, we have significantly de-risked the agonist program," says David Koos, Ph.D., Chairman & CEO Regen BioPharma Inc. "Using this information, we are now able to ramp up our inhibitor program which focuses on anti-cancer drugs."
About Zander Therapeutics Inc. and Entest BioMedical Inc.
Zander Therapeutics is a subsidiary of Entest BioMedical Inc. (ENTB), a publicly traded biotechnology company focused on veterinary medicine. The Company seeks to develop small molecule and immune stimulating therapies for veterinary applications.
Currently, the Company's major interest is in developing small molecule therapies for treating cancer and autoimmune diseases in animals, which include arthritis.
Zander Therapeutics Inc. is the exclusive licensee for veterinary applications of Regen BioPharma Inc.'s (RGBP) (RGBPP) intellectual property and technology relating to NR2F6. NR2F6 is a molecular switch known as an 'orphan nuclear receptor', which controls genes associated with the immune response. Zander Therapeutics is solely focused on veterinary applications.
Harry Lander serves as President and Chief Scientific Officer of Zander Therapeutics, Inc. and Regen BioPharma, Inc.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Zander Therapeutics, Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer